Form 10-Q Summary
Important identity discrepancy: The request identifies Kura Oncology, Inc., but the provided filing is for Zeta Acquisition Corp. III, a Delaware development-stage, blank-check shell company. The summary below reflects the filing text provided.
Business Context and Reporting Period
The filing covers the quarter ended March 31, 2013 and was filed May 15, 2013. Zeta Acquisition Corp. III was organized in November 2007 to identify and complete a business combination with an operating company. It had no active operating business, no identified target, and no revenue since inception.
The company reported 5,000,000 common shares outstanding as of May 15, 2013 and classified itself as a smaller reporting company, emerging growth company, development-stage company, blank-check company, and shell company.
Key Financial Metrics
| Metric | Q1 2013 | Q1 2012 | Change or Other Information |
|---|---|---|---|
| Revenue | $0 | $0 | No revenue since inception |
| Operating expenses | $4,716 | $4,241 | Primarily professional, legal, accounting, audit, and reporting costs |
| Interest expense | $1,257 | $1,131 | Related primarily to stockholder notes |
| Net loss | $5,973 | $5,372 | Loss increased by $601, or approximately 11% |
| Net loss per share | $0.00 | $0.00 | Basic and diluted; reported rounded amount |
| Cash flow from operations | $(1,901) | $(5,477) | Lower cash use than prior-year quarter |
| Cash flow from financing | $0 | $25,000 | No financing proceeds in Q1 2013 |
| Cash and cash equivalents, period end | $2,901 | $23,743 | Q1 2013 balance declined from $4,802 at December 31, 2012 |
At March 31, 2013, total assets were $4,026, including $2,901 of cash and $1,125 of prepaid expenses. Total liabilities were $105,345, including $85,000 of notes payable to stockholders, $12,555 of accrued interest, $6,290 of accounts payable, and $1,500 of accrued expenses. Stockholders’ deficit was $101,319.
The company had no investing cash flows. Cumulative net cash used in operating activities since inception was $132,099, while cumulative financing cash inflows were $135,000.
Material Changes Versus the Prior Comparable Period
- Net loss increased from $5,372 to $5,973.
- Operating expenses increased from $4,241 to $4,716.
- Interest expense increased from $1,131 to $1,257.
- Operating cash use improved from $5,477 to $1,901, principally because of changes in working capital.
- Unlike Q1 2012, the company received no stockholder financing during Q1 2013.
- Cash declined to $2,901 from $4,802 at December 31, 2012 and was substantially below the $23,743 reported at March 31, 2012.
- Total liabilities increased from $103,648 at December 31, 2012 to $105,345 at March 31, 2013.
Guidance, Outlook, Risks, and Unusual Items
Management planned to continue searching for a suitable acquisition candidate and expected to incur costs for SEC reporting and investigation, analysis, and potential consummation of an acquisition. No specific transaction, target, revenue forecast, or operating guidance was provided.
Management stated that the company’s ability to continue as a going concern depends on obtaining additional financing, generating future profitable operations, and completing a suitable business combination. Funding was expected, if available, from stockholders, management, other investors, related-party advances, or equity financing through a reverse merger. The filing states there is no assurance that additional financing will be available.
The stockholder notes are unsecured, bear interest at 6%, are due on demand, and totaled $85,000 at March 31, 2013. Accrued and unpaid interest was $12,555. The company had no material off-balance-sheet arrangements, no material pending legal proceedings, and no unregistered equity sales during the quarter.
Management concluded that disclosure controls and procedures were effective as of March 31, 2013, with no material changes in internal control over financial reporting during the quarter.
Facts Investors Should Verify
- Confirm the issuer identity: the supplied filing is for Zeta Acquisition Corp. III, not Kura Oncology, Inc.
- Verify the company’s shell-company status, lack of operating revenue, and absence of an identified business-combination target.
- Review the going-concern uncertainty and the company’s dependence on additional related-party or equity financing.
- Confirm the $2,901 cash balance against $105,345 of current liabilities and $85,000 of stockholder notes payable.
- Review the terms, maturity, interest accrual, and related-party nature of the stockholder notes.
- Assess the potential dilution and control implications of any future reverse merger or equity financing.